They designed an experimental model of MS by myelin oligodendrocyte glycoprotein (MOG)-induced experimental allergic encephalomyelitis (EAE) in CD200 null mice and witnessed accelerated pathological progression, as opposed to the delayed disease onset in the wild-type C57BL/6 rodents. This evidence concerns the gene CD200 and myeloid sarcoma.